istock-540832896_rs-photo-1
rs-photo / iStockphoto.com
21 November 2017Americas

Eli Lilly considers BMS trademark opposition

Eli Lilly appears to be mulling whether to oppose a trademark registered by Bristol-Myers Squibb (BMS) at the US Patent and Trademark Office.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Big Pharma
1 November 2017   The English Court of Appeal has ruled that patent claims protecting blockbuster drug Cialis (tadalafil) are invalid as obvious, handing victory to Actavis, Teva and Mylan.

More on this story

Big Pharma
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Big Pharma
1 November 2017   The English Court of Appeal has ruled that patent claims protecting blockbuster drug Cialis (tadalafil) are invalid as obvious, handing victory to Actavis, Teva and Mylan.

More on this story

Big Pharma
17 November 2017   The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Big Pharma
1 November 2017   The English Court of Appeal has ruled that patent claims protecting blockbuster drug Cialis (tadalafil) are invalid as obvious, handing victory to Actavis, Teva and Mylan.